Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenge Bushen Capsule of Xinjiang Huachun Biological Pharmaceutical Co., Ltd was approved for marketing by China NMPA.

Randomized, double-blinded, parallel group, placebo-controlled and multicenter clinical trials were conducted on this drug. The results showed that the difference between the score of the primary efficacy endpoint HAMD-17 and the baseline demonstrating the efficacy in the experimental group was better than that in the placebo-controlled group.

The medicine which replenishing Qi, nourishing Yin and tonifying kidney, is indicated to treat mild to moderate depression with TCM syndrome differentiation of Qi and Yin deficiency, and kidney Qi deficiency. The marketing of this drug provides another treatment option for patients with depression.